Adjuvant Aspirin Treatment for Colon Cancer Patients
Status:
Active, not recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
Following complete resection of their primary tumor, potentially eligible stage II or stage
III colon cancer patients will undergo central PIK3CA testing. Patients with somatic
mutations will be 2:1 randomized to daily aspirin 100 mg versus placebo for a total of 3
years or until disease recurrence, patient death or withdrawal of consent, whichever occurs
first. Patients will be followed up for 10 years from the date of surgery.
The intake of aspirin or placebo is independent of adjuvant chemotherapy, and does not impact
on the indication to give (or not to give) adjuvant chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Swiss Group for Clinical Cancer Research
Collaborators:
Central European Society for Anticancer Drug Research European Organisation for Research and Treatment of Cancer - EORTC